Primary tumor resection in de novo stage IV breast cancer patients

Breast and axillary surgery in Stage IV disease is outside current national guidelines but has been a topic of ongoing debate. A single institution retrospective study identified women with de novo stage IV BC from 2011‐2016 to evaluate the rate and goals of primary site surgery. Only 10.2% (n = 27/265patients) had primary site surgery. The goal of surgery was most often treatment intent (n = 23, 85.1%) not palliation (n = 4, 14.8%). There was no 30‐day mortality and low (n = 1, 3.7%) 30‐day morbidity. Multi‐disciplinary patient care pathways based on modern evidence may help identify patients potentially suitable for primary site surgery.